Myriad Genetics (MYGN) Misses Q3 EPS by 13c, Updates Guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $18.52 +0.65%
EPS Growth %: +116.7%
Financial Fact:
Total costs and expenses: 171.3M
Today's EPS Names:
IESC, FIZZ, DOMO, More
EPS Growth %: +116.7%
Financial Fact:
Total costs and expenses: 171.3M
Today's EPS Names:
IESC, FIZZ, DOMO, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.19), $0.13 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $156.4 million versus the consensus estimate of $170.58 million.
GUIDANCE:
Myriad Genetics sees FY2022 EPS of ($0.35)-($0.30), versus the consensus of ($0.06). Myriad Genetics sees FY2022 revenue of $668-672 million, versus the consensus of $692.2 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. economy adds 199,000 jobs in November
- Broadcom (AVGO) Tops Q4 EPS by 10c, Offers Guidance
- HashiCorp (HCP) Tops Q3 EPS by 7c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
